Short Interest in DBV Technologies S.A. (NASDAQ:DBVT) Rises By 297.0%

DBV Technologies S.A. (NASDAQ:DBVT) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,330,000 shares, an increase of 297.0% from the October 15th total of 335,000 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average daily volume of 655,300 shares, the days-to-cover ratio is presently 2.0 days.

DBV Technologies Trading Down 2.2 %

Shares of NASDAQ DBVT traded down $0.01 during trading on Wednesday, reaching $0.62. The company had a trading volume of 72,309 shares, compared to its average volume of 231,567. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.14. The business’s 50 day moving average price is $0.74 and its 200-day moving average price is $0.90.

DBV Technologies shares are set to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. HC Wainwright boosted their price target on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. Finally, StockNews.com assumed coverage on shares of DBV Technologies in a research note on Wednesday, November 6th. They set a “hold” rating on the stock.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.